Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It mentions a CEO becoming the first patient for HairClone.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

Stemson raised $15M for hair cloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

Finasteride and dutasteride can prevent hair loss if used early, but they may cause side effects. Many men shave their heads because they are unaware of these treatments or avoid them due to side effects or cost.

Stemson's presentation discussed using induced pluripotent stem cell technology to create new hair follicles for treating hair loss. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the role of DHT in male hair loss and the effectiveness of treatments like Finasteride, which reduces DHT, and RU58841, which blocks DHT from binding to scalp receptors. The user debates the trade-offs between maintaining hair and having a healthy endocrine system, suggesting RU58841 might allow for both.

A potential cure for balding might be available in about five years with advancements in artificial general intelligence. Current treatments like Minoxidil, finasteride, and RU58841 are still in use.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

The conversation humorously discusses hair loss treatments like finasteride, minoxidil, and dutasteride, referencing a "Smiling Friends" episode. It includes jokes about hair loss, AI-generated images, and the show's satire on societal perceptions of baldness.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation humorously discusses hair loss treatments, including finasteride, dutasteride, minoxidil, and microneedling. The user shares progress and thanks the pharmaceutical industry, with comments on the effectiveness and side effects of these treatments.

EdgeLord LLC's RU58841 is discussed for its authenticity and effectiveness in hair loss treatment, with suggestions to dissolve it in Kirkland minoxidil. Users express mixed opinions on the company's legitimacy and product value.

An Amazon service offering Finasteride/Dutasteride prescriptions for $5 per month in the US, and cheaper options in India and UK.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Bimatoprost (Latisse) may help with hair thinning but is expensive and less effective than minoxidil or finasteride. Combining treatments like minoxidil, finasteride, and possibly RU58841 could be more effective for hair loss.

The conversation discusses skepticism about AI's role in solving hair loss, with mentions of treatments like finasteride. Some users express hope that AI could aid research, while others doubt its effectiveness without medical testing.

The user shared seven months of progress using chewable finasteride 1.2 mg and minoxidil 3 mg, showing some improvement in hair thickness, particularly at the crown. Suggestions included continuing the medication for up to two years, considering a hair transplant, and maintaining consistency with the treatment.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Creatine may cause hair thinning for some, but experiences vary. Some users on finasteride report no hair loss from creatine, while others notice shedding that reverses after stopping creatine.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.